Tetracycline, Metronidazole, Bismuth subcitrate — Competitive Intelligence Brief

Tetracycline, Metronidazole, Bismuth subcitrate (Tetracycline, Metronidazole, Bismuth subcitrate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination therapy. Area: Gastroenterology / Infectious Disease.

marketed Antibiotic combination therapy Bacterial 30S ribosome (tetracycline), bacterial DNA (metronidazole), bacterial cell wall (bismuth) Gastroenterology / Infectious Disease Small molecule

Target snapshot

Tetracycline, Metronidazole, Bismuth subcitrate (Tetracycline, Metronidazole, Bismuth subcitrate) — Mackay Memorial Hospital. This triple-drug combination eradicates Helicobacter pylori by combining tetracycline's protein synthesis inhibition, metronidazole's DNA damage, and bismuth's bacterial cell wall disruption.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tetracycline, Metronidazole, Bismuth subcitrate TARGET	Tetracycline, Metronidazole, Bismuth subcitrate	Mackay Memorial Hospital	marketed	Antibiotic combination therapy	Bacterial 30S ribosome (tetracycline), bacterial DNA (metronidazole), bacterial cell wall (bismuth)
PPI-amoxicillin-clarithromycin	PPI-amoxicillin-clarithromycin	National Taiwan University Hospital	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; clarithromycin targets bacterial ribosome
ADJUNTIVE ANTIBIOTICS	ADJUNTIVE ANTIBIOTICS	University of Valencia	marketed	Antibiotic combination therapy
Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	Rabeprazole, metronidazole, Clarithromycin, Amoxicillin	American University of Beirut Medical Center	marketed	Proton pump inhibitor + antibiotic combination therapy	H+ ATPase (rabeprazole); bacterial ribosome and DNA (metronidazole, clarithromycin); bacterial cell wall (amoxicillin)
metronidazole based quadriple therapy	metronidazole based quadriple therapy	mohamed bouchoucha	marketed	Antibiotic combination therapy	Helicobacter pylori DNA and bacterial cell integrity
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis
Early Dual IV Antibiotic Therapy - MSSA	Early Dual IV Antibiotic Therapy - MSSA	West Virginia University	marketed	Antibiotic combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination therapy class)

1. West Virginia University · 2 drugs in this class
2. Mackay Memorial Hospital · 1 drug in this class
3. Takeda · 1 drug in this class
4. University of Valencia · 1 drug in this class
5. mohamed bouchoucha · 1 drug in this class